Resource Summary Report

Generated by NIF on Sep 14, 2026

U-87MG ATCC

RRID:CVCL_0022
Type: Cell Line

Proper Citation

RRID:CVCL_0022

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0022

Proper Citation: RRID:CVCL_0022

Description: Cell line U-87MG ATCC is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Glioblastoma

Defining Citation: PMID:327080, PMID:450131, PMID:833871, PMID:3518877, PMID:7459858, PMID:7763724, PMID:8069455, PMID:9090379, PMID:9230885, PMID:9842975, PMID:10074188, PMID:10402232, PMID:10416987, PMID:10560660, PMID:11414198, PMID:11416159, PMID:11966317, PMID:14614447, PMID:14655754, PMID:14961077, PMID:16232199, PMID:16697959, PMID:17595512, PMID:19365568, PMID:19435942, PMID:20126413, PMID:20164919, PMID:20215515, PMID:20587068, PMID:20593219, PMID:21406405, PMID:22282976, PMID:22460905, PMID:22570425, PMID:23325432, PMID:25877200, PMID:25894527, PMID:25960936, PMID:25984343, PMID:26496030, PMID:26589293, PMID:27397505, PMID:27412690, PMID:27582061, PMID:27894925, PMID:30894373, PMID:30971826, PMID:31068700, PMID:31978347, PMID:33385022

Comments: Population: Caucasian., Part of: Human Protein Atlas, Cell Atlas panel., Part of: ENCODE project common cell types; tier 3., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Problematic cell line: Misidentified. This cell line is not the original glioblastoma cell line established in 1968 at the University of Uppsala. As described in PubMed=27582061 it is most probably also a glioblastoma cell line but whose origin is unknow. See U-87MG Uppsala (Cellosaurus=CVCL_GP63) for the original U-87MG cell line..

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: U-87MG ATCC

Synonyms: U-87MG, U-87 MG, U87 MG, U-87-MG, U87-MG, U87MG, U-87, U87, 87 MG, 87MG

Cross References: BTO:BTO_0002036, CLO:CLO_0009463, CLO:CLO_0009464, EFO:EFO_0005237, MCCL:MCC:0000469, CLDB:cl4592, CLDB:cl4594, CLDB:cl4595, CLDB:cl7166, Abcam:ab278079, AddexBio:C0005002/71, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:HTB-14, BCRC:60360, BCRJ:0241, BEI_Resources:ARP-2188, BioGRID_ORCS_Cell_line:348, BioSample:SAMN03472715, BioSample:SAMN03473126, BioSample:SAMN05292456, BioSample:SAMN07710026, BioSample:SAMN07710027, BioSample:SAMN07710028, BioSample:SAMN07710029, BioSample:SAMN07710030, BioSample:SAMN07710031, BioSample:SAMN07710032, BioSample:SAMN10988360, cancercelllines:CVCL_0022, CCRID:1101HUM-PUMC000208, CCRID:3101HUMTCHu138, CCTCC:GDC0157, Cell_Model_Passport:SIDM01189, CGH-DB:157-1, ChEMBL-Cells:CHEMBL3307575, ChEMBL-Cells:CHEMBL3989361, ChEMBL-Targets:CHEMBL614247, CLS:300367, Cosmic:687590, Cosmic:849853, Cosmic:850741, Cosmic:850822, Cosmic:920816, Cosmic:1036336, Cosmic:1064099, Cosmic:1066234, Cosmic:1171224, Cosmic:1175825, Cosmic:1198263, Cosmic:1217671, Cosmic:1219449, Cosmic:1237542, Cosmic:1294951, Cosmic:1610737, Cosmic:1746951, Cosmic:1945859, Cosmic:2302316, Cosmic:2367555, Cosmic:2491106, Cosmic:2516044, Cosmic:2550364, Cosmic:2568870, Cosmic:2580918, Cosmic:2701083, Cosmic-CLP:687590, DepMap:ACH-000075, ECACC:89081402, EGA:EGAS00001000978, ENCODE:ENCBS424ENC, GDSC:687590, GEO:GSM101676, GEO:GSM101686, GEO:GSM101687, GEO:GSM101688, GEO:GSM326243, GEO:GSM481417, GEO:GSM500897, GEO:GSM887723, GEO:GSM888817, GEO:GSM923437, GEO:GSM1374974, GEO:GSM1638668, GEO:GSM1670559, GEO:GSM2113436, GEO:GSM2113437, GEO:GSM2113438, GEO:GSM2113439, GEO:GSM7701418, GEO:GSM7701419, IARC_TP53:21096, IBRC:C10982, ICLC:HTL00013, IZSLER:BS TCL 189, KCB:KCB 2011101YJ, KCLB:30014, LiGeA:CCLE_552, LINCS_HMS:50868, LINCS_LDP:LCL-1364, Lonza:37, Lonza:808, MetaboLights:MTBLS4708, MetaboLights:MTBLS6212, NCBI_Iran:C531, PharmacoDB:U87MG_1623_2019, PRIDE:PXD000589, PRIDE:PXD000661, PRIDE:PXD001565, PRIDE:PXD003790, Progenetix:CVCL_0022, PubChem_Cell_line:CVCL_0022, RCB:RCB0419, TOKU-E:3381, Ubigene:YC-C028, Wikidata:Q7863603

ID: CVCL_0022

Record Creation Time: 20220427T221639+0000

Record Last Update: 20260913T010247+0000

Ratings and Alerts

No rating or validation information has been found for U-87MG ATCC.

Warning: Problematic cell line: Misidentified. This cell line is not the original glioblastoma cell line established in 1968 at the University of Uppsala. As described in

PubMed=27582061 it is most probably also a glioblastoma cell line but whose origin is unknow. See U-87MG Uppsala (CVCL_GP63) for the original U-87MG cell line.

Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00535.
Population: Caucasian., Part of: Human Protein Atlas, Cell Atlas panel., Part of: ENCODE project common cell types; tier 3., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Problematic cell line: Misidentified. This cell line is not the original glioblastoma cell line established in 1968 at the University of Uppsala. As described in PubMed=27582061 it is most probably also a glioblastoma cell line but whose origin is unknow. See U-87MG Uppsala (Cellosaurus=CVCL_GP63) for the original U-87MG cell line.. Warning: Discontinued: RCB; RCB0419
Population: Caucasian., Part of: Human Protein Atlas, Cell Atlas panel., Part of: ENCODE project common cell types; tier 3., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Problematic cell line: Misidentified. This cell line is not the original glioblastoma cell line established in 1968 at the University of Uppsala. As described in PubMed=27582061 it is most probably also a glioblastoma cell line but whose origin is unknow. See U-87MG Uppsala (Cellosaurus=CVCL_GP63) for the original U-87MG cell line..

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 3470 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Wang Y, et al. (2026) Metabolic reinvigoration of NK cells by IL-21 enhances immunotherapy against MHC class I-deficient solid tumors. Cell reports, 45(3), 117035.

Pineau D, et al. (2026) EDNRB-dependent endothelin signaling reduces proliferation and promotes proneural-to-mesenchymal transition in gliomas. Molecular oncology.

Lu B, et al. (2026) Targeting the tumor microenvironment: reprogramming macrophages as a novel therapeutic strategy in FUOM-deficient glioblastoma. Cell death & disease, 17(1).

Dolci S, et al. (2026) Tumor-associated macrophages enhance peripheral nerve tumor infiltration and spinal cord repair. Immunity, 59(2), 438.

de Gooijer MC, et al. (2026) Disconnect between in vitro and in vivo efficacy of the MPS1 inhibitor NTRC 0066-0 against glioblastoma. Cellular oncology (Dordrecht, Netherlands), 49(2), 46.

Dai W, et al. (2026) An IGF2BP3-dependent metabolic circuit governs macrophage recruitment and immunosuppression in glioblastoma. Cell reports, 45(7), 117643.

Yang X, et al. (2026) Conformationally Tuned Cyclic RGD Peptides for Integrin-Subtype-Selective PET/CT Imaging. Journal of medicinal chemistry, 69(14), 17054.

Abdi K, et al. (2026) miR-132 overexpression is associated with modulation in miR-21 expression and glioblastoma cell behavior. PloS one, 21(7), e0352119.

Lan TH, et al. (2026) A single-component optogenetic toolkit for reversible visualization and programmable control of microtubule dynamics. Cell reports methods, 101532.

Yang F, et al. (2026) SMARCA4 deficiency in glioblastoma: Mitochondrial transfer from MSCs and the clinical dilemma in targeting the tumor microenvironment. Neoplasia (New York, N.Y.), 73, 101288.

Zhao K, et al. (2026) Aromatic amino acid metabolism shapes autophagy-mediated adaptation to iron deprivation in glioblastoma cells. Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine, 39(3), 1167.

Tao F, et al. (2026) An atom-edged magnetic nanomotor for cancer mechanotherapy. iScience, 29(3), 114994.

Lobb RJ, et al. (2026) Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature. Cell reports. Medicine, 7(4), 102694.

Cheng M, et al. (2026) YTHDF3 facilitates DNA damage response by recognizing METTL3-mediated m6A modification to promote chemotherapy resistance in glioblastoma. Cancer letters, 649, 218445.

Oksal MD, et al. (2026) IDH1 mutation promotes angiogenesis via upregulation of hypoxia inducible factor 1 alpha in glial tumors. Mutation research, 833, 111939.

Rurka P, et al. (2026) A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose-driven glioblastoma. Molecular oncology.

Krygier K, et al. (2026) A covalent peptide engager approach to equip immunotherapeutic monoclonal and pan IgG serum antibodies with new tumour-targeting function. British journal of pharmacology.

Jin Z, et al. (2026) Novel Covalent FAP-Targeted [68Ga]Ga-DOTA-mFS-KERERG-FAP-2286 for Improved Pharmacokinetics and Enhanced Tumor Uptake. Molecular pharmaceutics, 23(6), 3468.

Fang Y, et al. (2026) NFYC upregulates KLF1 expression and activate LDHA to drive glycolysis and tumor growth in glioblastoma cells. Frontiers in cell and developmental biology, 14, 1810731.

Sultana S, et al. (2026) Targeting Cancer Cells With Co(III)-Bipyridyl Complex: A Combined In Vitro and In Silico Study on U87MG and ME-180 Cell Lines. Chemistry & biodiversity, 23(6), e71370.